Overview

Novel Treatment Option for Neuropathic Pain

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the EGFR-inhibitor cetuximab is better than placebo for the treatment of neuropathic pain.
Phase:
Phase 2
Details
Lead Sponsor:
Sorlandet Hospital HF
Collaborators:
Frontier Science & Technology Research Foundation, Inc.
Merck KGaA
Merck KGaA, Darmstadt, Germany
Treatments:
Cetuximab